QPPV.COM KNOWLEDGE ASSESSMENT

Emerging Safety Issue Assessment: Evidence, Urgency and Regulatory Decision-Making

Test your understanding of the concepts covered by Emerging Safety Issue Assessment: Evidence, Urgency and Regulatory Decision-Making.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A large randomised clinical trial identifies an unexpected excess of fatal events before any conventional spontaneous-report signal has developed. What should the MAH do first?

Wait until disproportionality analysis confirms the finding Wait until formal signal validation is completed Assess the concern as a potential ESI based on the available trial evidence and urgency Treat the finding only as an individual case-reporting issue

Question 2 of 10 A suspected falsified medicine causes patient harm and also raises a pharmacovigilance concern. What is the most appropriate regulatory approach?

Use the ESI process as a universal substitute for all other procedures Ignore the safety concern because falsification is not a pharmacovigilance issue Identify and use the applicable falsified-medicine or quality pathway, while assessing whether a separate ESI or other safety pathway also applies Report only individual cases and take no product-quality action

Question 3 of 10 A regulator outside the EU introduces a contraindication for the same active substance. What is the most appropriate MAH response?

Apply the contraindication automatically in the EU without assessment Ignore it because it is not an EU regulatory action Promptly assess the underlying evidence, product and population relevance, EU exposure and whether the action is interim or confirmed Wait for an identical number of EU cases before reviewing it

Question 4 of 10 Which limitation is particularly important when interpreting a clinical-trial finding about a rare adverse event?

Randomisation makes all trial findings irrelevant to safety Small sample size or short follow-up may limit detection and interpretation of rare or delayed events Controlled exposure prevents any assessment of causality Trial data cannot contribute to ESI assessment until marketing authorisation

Question 5 of 10 What is the most appropriate interpretation of a coherent latency pattern across several cases?

It proves that the medicine caused the events It contributes to the overall causal assessment but does not establish causality alone It is irrelevant unless positive rechallenge is present It establishes the incidence of the reaction

Question 6 of 10 Which statement best describes the relationship between causal certainty and urgency?

Urgent attention is justified only when causality is fully established Low causal certainty always means routine monitoring is sufficient Causal certainty and potential impact are separate dimensions, so severe, preventable and widespread potential harm may warrant urgent attention despite uncertainty Urgency can replace the need for scientific assessment

Question 7 of 10 What regulatory reasoning is illustrated by the domperidone example?

Every serious cardiac risk requires withdrawal Risk can sometimes be managed through restrictions on indication, dose, duration, contraindications and warnings Known risks do not require benefit-risk assessment A regulatory action proves that causality was certain from the outset

Question 8 of 10 Which question best operationalises the urgency component of ESI assessment?

Has the association achieved statistical significance in every available dataset? Could patients or public health experience avoidable serious harm if the concern followed only the ordinary assessment timetable? Has the adverse event already been added to the product information? Is the number of reports higher than for every other adverse event?

Question 9 of 10 What did the valproate example primarily demonstrate from an ESI-assessment perspective?

Only newly discovered adverse effects can require regulatory action An established risk can create a new regulatory problem when evidence shows existing risk-minimisation measures are insufficient Risk-minimisation measures are unnecessary once a risk is included in product information Regulatory action for teratogenicity always requires product withdrawal

Question 10 of 10 A medicine has a pharmacological effect that could theoretically cause a particular organ injury, but clinical evidence is limited. What is the correct interpretation?

The mechanism proves that the injury occurs clinically The mechanism supports plausibility but does not establish clinical frequency, causality or importance The mechanism is irrelevant unless a regulatory authority has acted The mechanism establishes a dose-response relationship

Emerging Safety Issue Assessment: Evidence, Urgency and Regulatory Decision-Making

Cookie Settings